Early Detection of Advanced Adenomas and Colorectal Cancer
Conditions: Colorectal Cancer; Colorectal Neoplasms; Colorectal Polyp; Colorectal Adenocarcinoma; Colorectal Disorders; Colorectal Dysplasia; Colorectal Cancer Stage I; Colorectal Cancer Stage II; Colorectal Cancer Stage III; Colorectal Cancer Stage IV; Colorectal Neoplasms Malignant; Colorectal Serrated Adenocarcinoma; Colorectal Adenoma With Severe Dysplasia; Colorectal Adenoma With Mild Dysplasia; Colorectal Adenoma With Moderate Dysplasia; Colorectal Adenoma and Carcinoma 1; Colorectal Adenomatous Polyp; Colorectal Adenocarcinoma Metastatic in the Liver Interventions: Diagnostic Test: DENEB Sponsors: City of Hope Medic...
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy
Conditions: Lung Cancer; Liver Cancer; Pancreatic Cancer; Renal Cell Carcinoma Interventions: Radiation: SBRT Sponsors: Peking University Third Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Cholangiocarcinoma; Primary Liver Cancer; Primary Liver Carcinoma; Hepatic Cancer; Hepatic Carcinoma Interventions: Diagnostic Test: ELUCIDATE Sponsors: City of Hope Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma Interventions: Drug: BBO-8520; Drug: Pembrolizumab Sponsors: TheRas, Inc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Concurrent Programmed Cell Death Protein 1 Inhibitor and Radiotherapy With Immunonutrition Support for in Unresectable Esophageal Squamous Cell Carcinoma Patients
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma; Sintilimab; Radiotherapy; Concurrent Chemoradiotherapy; Immunonutrition Interventions: Combination Product: Sintilimab + radiotherapy + enteral nutritional emulsion (TPF-T) Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma; Sintilimab; Radiotherapy; Concurrent Chemoradiotherapy; Immunonutrition Interventions: Radiation: Radiotherapy; Drug: Programmed Cell Death Protein 1 Inhibitor; Dietary Supplement: Immunonutrition support Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Radiation: Photon radiotherapy Sponsors: Chang Gung Memorial Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
Conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Interventions: Drug: Adebrelimab; Drug: Apatinib; Drug: Tegafur Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Conditions: Breast Cancer; Axillary Metastases Interventions: Procedure: Targeted axillary dissection (TAD) by ICG; Procedure: Targeted axillary dissection (TAD) by Blue patent Sponsors: Hospital Universitari de Bellvitge Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
Conditions: Chromophobe Renal Cell Carcinoma; Clear Cell Papillary Renal Tumor; Clear Cell Renal Cell Carcinoma; Kidney Oncocytoma; Papillary Renal Cell Carcinoma; Urothelial Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
HPV Immunological Markers of Cervical Persistent Infection and Oncogenesis
Conditions: HPV-Related Cervical Carcinoma Sponsors: Foundation IRCCS San Matteo Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
Conditions: Breast Carcinoma Interventions: Other: Non-Interventional Study Sponsors: University of Southern California; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Conditions: Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma; Triple-negative Breast Cancer; Lung Cancer; Colorectal Cancer; Gastric Cancer; Ovarian Cancer; Pancreatic Cancer Interventions: Drug: Diagnostic Test: MNPR-101-DFO*-89Zr PET Scan Sponsors: Monopar Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma Interventions: Drug: INCB099280 Sponsors: Abramson Cancer Center at Penn Medicine; Incyte Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
" Ultra-High Frequency intraOral UltraSonography of the TONgue " (HOUSTON)
Conditions: Oral Squamous Cell Carcinoma Interventions: Device: Ultrasound Sponsors: University of Pisa Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
